Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Rak neznanega izvora : nas izvor bolezni še zanima
Authors:ID Matos, Erika (Author)
ID Pavlović Djokić, Snežana (Author)
ID Novaković, Srdjan (Author)
ID Čakš, Marina (Author)
ID Devjak, Rok (Author)
ID Hribernik, Nežka (Author)
ID Cankar, Kaja (Author)
Files:.pdf PDF - Presentation file, download (2,83 MB)
MD5: 163AA599DA2A976A118DCFF310F39E43
 
Language:Slovenian
Typology:1.04 - Professional Article
Organization:Logo OI - Institute of Oncology
Abstract:Rak neznanega izvora (RNI) je opredeljen kot karcinom ali nediferencirana neoplazma, pri kateri z naborom standardnih diagnostičnih postopkov ni mogoče odkriti izvornega mesta bolezni. Tradicionalno RNI delimo v dve podskupini, pri čemer le približno 15 % primerov predstavlja prognostično ugodno skupino. Velika večina bolnikov spada v prognostično neugodno skupino in ima ob prvi prezentaciji obsežno breme bolezni. Možnosti zdravljenja so omejene, izidi bolnikov, zdravljenih z empirično kemoterapijo (KT) s platino ali taksani, pa so še vedno slabi, srednje celokupno preživetje je manj kot 10 mesecev. Za mnoge bolnike ostaja optimalna izbira najboljše možno podporno zdravljenje. Novi pristopi k obravnavi teh bolnikov se zdijo obetavni in so temeljit premik v paradigmi zdravljenja RNI; od zdravljenja, specifičnega za organ/tkivo, k zdravljenju, usmerjenemu na posameznega bolnika, ki temelji na genomskih spremembah njegovega tumorja. Prispevek povzema trenutne dokaze o uporabi vsakega od teh pristopov. Predstavljeno je tudi zdravljenje treh bolnikov z neugodnim RNI.
Keywords:rak neznanega izvora, molekularne značilnosti, biološki označevalci
Publication status:Published
Publication version:Version of Record
Publication date:01.06.2024
Publisher:Onkolološki inštitut
Year of publishing:2024
Number of pages:str. 62-68
Numbering:Letn. 28, št. 1
Source:Ljubljana
PID:20.500.12556/DiRROS-19905 New window
UDC:616-006
ISSN on article:1408-1741
COBISS.SI-ID:200508931 New window
Copyright:by Authors
Publication date in DiRROS:26.07.2024
Views:6
Downloads:3
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Onkologija
Shortened title:Onkologija
Publisher:Onkološki inštitut
ISSN:1408-1741
COBISS.SI-ID:65324032 New window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:30.06.2024

Secondary language

Language:English
Title:Cancer of unknown primary : does primary still matter
Abstract:Cancer of unknown primary (CUP) is defined as a carcinoma or undifferentiated neoplasm in which a standardized diagnostic workup fails to identif y the primary tumour responsible for me-tastatic seeding. Survival after diagnosis of CUP remains poor and has not improved significantly over time. Traditionally, CUP has been divided into two subsets, with only about 15% of cases in the favourable subset. The vast majority of patients are in the unfa-vourable subset and present with a high metastatic burden at first presentation. Their treatment options are limited and outcomes for patients treated with empiric chemotherapy consisting of platinum- or taxane-based doublets remain poor, with median overall survival of less than 10 months. Best supportive care remains the best treatment option for many patients. Some novel approaches to the treatment of patients with CUP are promising and represent a fundamental shift in the paradigm of cancer treatment from organ/tissue-specific to individual patient-focused treatment based on tumour-specific genomic alterations. This paper summarizes the current evidence on the application of each of these approaches. The treatment of three clinical cases with unfavourable CUP using novel approaches is presented.


Back